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ABSTRACT Protein I (P.I) is the major outer membrane
protein ofNeisseriagonorrhoeae and serves as a porin. By using
oligonucleotide probes derived from the known amino-terminal
sequence of the mature protein, we have cloned the gene
encoding the P.1 ofgonococcal strain FA19 in three overlapping
fragments and determined the DNA sequence. The gene
sequence predicts a protein with characteristics typical of the
porins of other Gram-negative bacteria. A clone expressing P.I
in Escherichia coli was obtained by removing a portion of the
P.1 gene promoter and reconstructing the entire P.I gene in a
position just downstream from a phage T7 promoter. Expres-
sion of P.I was then achieved by introducing this recombinant
plasmid into an E. coli strain containing an inducible T7
polymerase gene. The clone produced a protein that was
identical in size to native P.I and reacted with anti-P.I
monoclonal antibodies. Prolonged expression of the protein
apparently was lethal for E. coli, possibly explaining failures to
clone an intact P.I gene with its own promoter.
The outer membrane of Neisseria gonorrhoeae includes a
variety of proteins, the most abundant of which is known as
protein I (P.I). P.1 is a matrix or porin protein (1), forming an
aqueous channel for the selective passage of solutes through
the outer membrane. Like the porins of other Gram-negative
bacteria, gonococcal P.I exists as a trimer in the outer
membrane (2) and forms a pore similar in size to that of the
major porins of Escherichia coli (3). P.I is a major antigen on
the gonococcal cell surface and it may have pathogenic
properties in addition to its porin activity. It is able to insert
directly into artificial bilayer membranes and into human
erythrocytes when gonococci are mixed with these cells (4),
though the significance of this event and whether it takes
place in vivo are unknown. Antibodies against P.1 are opsonic
(5), and P.1 has been associated with gonococcal serum
resistance (6) and inactivation of polymorphonuclear leuko-
cyte degranulation (4). The universal occurrence of this
protein in gonococci and its comparatively conserved nature
make it attractive as a component of a gonorrhea vaccine.
There are two immunochemical classes of P.1, termed P.IA
and P.IB. Different serovars of P.IA and P.IB are defined by
reactions with a set of monoclonal antibodies (7). The P.I
proteins of the two serotypes show other structural differ-
ences. P.IB proteins have an apparent molecular weight by
NaDodSO4/polyacrylamide gel electrophoresis of 34,000-
38,000 and are susceptible to cleavage by the proteolytic
enzymes trypsin and chymotrypsin, whereas P.IA proteins
normally have a slightly lower apparent molecular weight and
are resistant to these proteolytic enzymes (8).
Genetic studies of P.1 in the gonococcus have been limited.
A locus designated nmp is known to affect the molecular
weight and antigenicity of P.1 (9) and is closely linked to loci
involved in serum resistance (sac) and antibiotic resistance
(penB, str, spc) (10). It is not known whether the nmp locus
is the structural gene for P.1 or a regulatory gene affecting
expression of the structural gene located elsewhere. Cloning
of the P.1 structural gene has presented problems; a portion
of the P.IB gene of gonococcal strain MS11 has apparently
been cloned in E. coli (11), but a full report of these results
has not been published. Reasons for difficulty in cloning this
biologically important protein have been unclear.
In this paper, we report the cloning and characterization of
the structural gene for the P.IA of gonococcal strain FA19
and its expression under the control of a foreign promoter in
E. coli.*
MATERIALS AND METHODS
Bacterial Strains and Plasmids. The N. gonorrhoeae strain
used in this study was FA19 (P.IA) (12). E. coli strain HB101
has been described previously (13), and BL21(DE3) (14), a
generous gift from F. William Studier (Brookhaven National
Laboratory, Upton, NY), is a lysogen in which the phage T7
polymerase gene is present but under the control of the
lacUVS promoter. Plasmids used were pBR322 (13) and
pGEM-2 obtained from Promega Biotec (Madison, WI).
Media. N. gonorrhoeae was grown in GC base medium
(Difco) containing Kellogg's supplements I and II (15) in a 5%
C02/95% air atmosphere. E. coli strains were grown in Luria
medium (13) with the following additions where appropriate:
ampicillin (50 ,ug/ml), tetracycline (10 Ag/ml), and isopropyl
(-D-thiogalactopyranoside (iPrSGal; 100 ptg/ml).
Colony Blot Radioimmunoassay and Imnunoblotting. Bac-
terial colonies were assayed for binding of monoclonal
antibodies by the method of Cannon et al. (16). The mono-
clonal antibodies used to detect P.IA were 4A12, 4G5, 2F12,
6D9, 5G9, and 5D1 (7). Immunoblotting was performed
according to the method of Burnette (17). After NaDodSO4/
polyacrylamide gel electrophoresis of whole cell lysates in a
Laemmli buffer system (18), transfer for immunoblotting and
P.1 detection were carried out as described previously (19).
DNA Techniques. Gonococcal genomic DNA was prepared
by the method of Stern et al. (20). Preparation of plasmid
DNA and transformation into E. coli were performed as
described by Maniatis et al. (13). Restriction endonucleases,
DNA polymerase Klenow fragment, T4 DNA ligase, and
polynucleotide kinase were obtained from either Bethesda
Research Laboratories or New England Biolabs and were
used according to the instructions of the manufacturer.
Abbreviations: P.1, protein I of N. gonorrhoeae; iPrSGal, isopropyl
P-D-thiogalactopyranoside; bp, base pair(s); kb, kilobase pair(s).
*The sequence reported in this paper is being deposited in the
EMBL/GenBank data base (Bolt, Beranek, and Newman Labora-
tories, Cambridge, MA, and Eur. Mol. Biol. Lab., Heidelberg)
(accession no. J03029).
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Oligonucleotide Synthesis. Oligonucleotides were synthe-
sized in an Applied Biosystems (Foster City, CA) DNA
synthesizer, model 380A, and purified by electrophoresis on
a 20% polyacrylamide/45% urea gel followed by elution of
the DNA from a gel slice in 0.5 M ammonium acetate.
Southern Blotting and DNA Hybridization. Restriction
endonuclease-digested DNA was transferred from agarose
gels onto nitrocellulose by the method of Southern (21). For
colony hybridization, bacterial colonies were transferred
onto nitrocellulose filters that were prepared for hybridiza-
tion according to the method of Grunstein and Hogness (22).
Oligonucleotides were labeled with [_y-32P]ATP (ICN) using
polynucleotide kinase following the method of Maniatis et al.
(13). Hybridization of labeled oligonucleotides to DNA on
nitrocellulose filters was carried out overnight in 4x SSPE
(lx SSPE is 0.18 M NaCl/10 mM NaH2PO4, pH 7.4/1 mM
EDTA)/2x Denhardt's solution (13)/20 mM sodium pyro-
phosphate/0.2% NaDodSO4 containing salmon sperm DNA
at 50 ,ug/ml and with 106 cpm of labeled oligonucleotide per
ml of hybridization buffer. Filters were washed with 1 x SSC
(0.15 M NaCl/0.015 M sodium citrate)/5 mM sodium pyro-
phosphate/0.1% NaDodSO4. Hybridization and wash tem-
peratures for each oligonucleotide were determined by the
formula [2 x (A + T) + 4 x (G + C) - 10]0C (23). Thus, the
temperatures used for oligonucleotides 1 and 2 (Fig. 1) were
46°C and 40°C, respectively. Filters were rinsed with 5 x
SSC, dried, and exposed to Kodak x-ray film.
RESULTS
Design of Synthetic Oligonucleotides and Hybridization with
N. gonorrhoeae DNA. Using monoclonal antibodies to detect
P.1 epitopes, attempts to clone P.1 in pBR322 or other vector
plasmids in HB101 were repeatedly negative, and it was
concluded that either gonococcal P.I is lethal for HB101 or
the monoclonal antibodies did not recognize the protein when
expressed in E. coli. Therefore oligonucleotides derived from
the N-terminal amino acid sequence of P.I of strain R10
(P.IB) (2) were synthesized for use as hybridization probes to
clone P.I gene sequences (Fig. 1). A limited amount of codon
usage data for N. gonorrhoeae was obtained from the gene
sequences of pilin (24) and protein II (J. Cannon, personal
communication). Oligonucleotides NC1 and NC2 were de-
signed based on this information, oligonucleotide NC1 as a
unique sequence and oligonucleotide(s) NC2 as a mixed
population to increase the probability of obtaining the correct
sequence. In a colony hybridization assay, both these oligo-
nucleotides hybridized to FA19 but not to HB101 containing
the vector plasmids pBR322 or pGEM-2 (data not shown).
Southern hybridization of genomic restriction digests of
FA19 DNA probed with oligonucleotide NC1 showed hy-
bridization to a single fragment in each case; the sizes of the
relevant fragments were EcoRI, 10 kilobase pairs (kb); Sal I,
5.5 kb; Sau3AI, 900 base pairs (bp); Taq I, 750 bp (data not
shown). Results were identical with oligonucleotides NC1
and NC2.
Cloning and Sequencing of the P.1 Gene Fragments of FA19.
When libraries of HB101 colonies containing EcoRI-digested
or Sal I-digested FA19 DNA cloned into pBR322 were
probed with oligonucleotide NC1 by colony hybridization, no
positive colonies were found, further supporting the idea that
P.I is lethal for E. coli. This suggested that the smaller
oligonucleotide NC1-hybridizing fragments in the Sau3AI
and Taq I digests of FA19 DNA, which presumably did not
contain a complete P.I gene, would be more suitable candi-
dates for cloning. Total FA19 DNA was digested to comple-
tion with Sau3AI, ligated with BamHI-digested pGEM-2
DNA and transformed into HB101. Of -2000 transformants,
one colony hybridized to oligonucleotide NC1. Plasmid DNA
was prepared from this clone, digested with Sau3AI and
probed with oligonucleotide NC1 by Southern hybridization.
A single fragment of 900 bp, the same size as the Sau3AI
genomic fragment of FA19 identified by Southern hybridiza-
tion, hybridized with the oligonucleotide. This fragment was
recovered from an agarose gel and religated into BamHI-
digested pGEM-2 to create the recombinant plasmid pUNC3
(Fig. 2). The same strategy was used to clone the 750-bp Taq
I fragment ofFA19DNA that hybridized with oligonucleotide
NC1 into the Acc I site of pGEM-2, resulting in formation of
the recombinant plasmid pUNC11 (Fig. 2).
The DNA sequence of the 750-bp Taq I fragment was
determined by first subcloning smaller (<300 bp) restriction
fragments derived from the Taq I fragment into M13mpl8
replicative form DNA (25) and sequencing these by the
method of Sanger et al. (26). From this sequence a 17-
nucleotide oligonucleotide was synthesized corresponding to
the sequence just downstream of the Sau3AI site in the P.1
gene (Fig. 2). This oligonucleotide, designated NC8, was
used to identify by Southern hybridization an 850-bp Sau3AI
fragment of FA19 DNA adjacent to the 900-bp fragment
previously cloned, and this 850-bp Sau3AI fragment was
cloned into pGEM-2 (to give pUNC15, Fig. 2) and sequenced
using the strategies described above. The sequence of the P.1
gene is shown in Fig. 3. The only large open reading frame in
this sequence lies between bases 84 and 1062, which corre-
sponds to a protein of 326 amino acids. From the published
N-terminal amino acid sequence of various P.1 proteins (27),
the first residue of the mature protein presumably is aspartic
acid at base 141, giving a mature protein of 307 amino acids
and a signal peptide of 19 amino acids. The predicted
500 bp
1 2 3 4 5 6 7 8 9 10 11 12
protein Asp-Val-Thr-Leu-Tyr-Gly-Ala-Ile-Lys-Ala-Gly-Val
mRNA 5' GAU GUU ACU CUW UAU GGU GCU AUU AAA GCU GGU GU 3'
C C C UC C C C C G C C
A A A A A A A A
G G G G G G G
oligo NC1-.-3' CGG TAG TTT CGG CCG CA 5'




FIG. 1. Amino acid sequence of residues 1-12 of P.1 of strain R10
(2), the encoding mRNA sequence including degenerate bases, and
the oligonucleotides synthesized. Where degeneracy occurred, se-
quences were chosen based on codon usage data from other






FIG. 2. Sau3AI and Taq I fragments of FA19 genomic DNA
including portions of the P.1 gene. Fragments were cloned into the
vector plasmid pGEM-2, resulting in recombinant plasmids having
the designations shown above. The relative position of the P.I coding
region on the genome is indicated by the open box above (the shaded
box corresponds to the N-terminal signal sequence) and the relative
position of the oligonucleotide probes is shown below the fragments.
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-35 -10 RBS Met Lys Lys Ser Leu Ile Ala Leu Thr
AGCCCCTCGGCGGTAAATGCAAAGCTAAGCGGCTTGGAAAACCCGGCCTGCTTAAATTTCTTAACCAAAAAAGGAATACAGCA ATG AAA AAA TCC CTG ATT GCC CTG ACT
HaeIII
Leu Ala Ala Leu Pro Val Ala Ala Met Ala Asp Val Thr Leu Tyr Gly Thr Ile Lys Ala Gly Val Glu Thr Ser Arg Ser Val Ala His
TTG GCA GCC CTT CCT GTT GCA GCA ATG GCT GAC GTT ACC CTG TAC GGC ACC ATC AAA GCC GGC GTA GAA ACT TCC CGC TCC GTA GCT CAC
-signal peptide
His Gly Ala Gin Ala Asp Arg Val Lys Thr Ala Thr Glu Ile Ala Asp Leu Gly Ser Lys Ile Gly Phe Lys Gly Gin Glu Asp Leu Gly
CAT GGA GCT CAG GCG GAT CGC GTT AAA ACC GCT ACC GAA ATC GCT GAT TTG GGT TCG AAA ATC GGC TTT AAA GGC CAA GAA GAC CTC GGC
Sau3AI TagI
Asn Gly Leu Lys Ala lie Trp Gin Leu Glu Gin Lys Ala Tyr Val Ser Gly Thr Asp Thr Gly Trp Gly Asn Arg Gin Ser Phe lie Gly
AAC GGC CTG AAA GCC ATT TGG CAG TTG GAA CAA AAA GCC TAC GTC AGC GGT ACT GAC ACA GGC TGG GGC AAC CGC CAA TCC TTC ATC G(T
Leu Lys Gly Gly Phe Gly Lys Val Arg Val Gly Arg Leu Asn Ser Val Leu Lys Asp Thr Gly Gly Phe Asn Pro Trp Glu Gly Lys Ser
TTG AAA GGC GGC TTC GGT AAA GTG CGC GTC GGC CGT TTG AAC AGC GTC CTG AAA GAC ACC GGC GGC TTC AAT ccT TGG GAG GGT AAA AGC
Tyr Tyr Leu Gly Leu Ser Asn lie Ala Gin Pro Glu Glu Arg His Val Ser Val Arg Tyr Asp Ser Pro Glu Phe Ala Gly Phe Arg Ala
TAC TAT TTG GGT TTA AGC AAC ATT GCC CAA CCC GAA GAA CGC CAC GTT TCC GTA CGC TAC GAT TCT CCC GAA TTT GCC GGC TTC AGG CCA
Val Gin Tyr Val Pro Asn Asp Asn Ser Gly Lys Asn His Ser Glu Ser Tyr His Ala Gly Phe Asn Tyr Lys Asn Ser Gly Phe Phe Val
GTG CAA TAC GTG ccGr AAC GAC AAT TCG GGC AAA AAT CAC AGC GAA TCT TAC CAT GCA GGC TTC AAC TAC AAA AAC AGC GGC TTC TITC GTG
Gin Tyr Ala Gly Phe Tyr Lys Arg His Ser Tyr Thr Thr Glu Lys His Gin Val His Arg Leu Val Gly Gly Tyr Asp His Asp Ala Leoi
CAA TAT GCC GGC TTC TAT AAA AGA CAT AGT TAC ACG ACT GAG AAA CAC CAG GTT CAC CGT TTG GTC GGC GGT TAC GAC CAT GAT (CC CGG
Tyr Ala Ser Val Ala Val Gin Gin Gin Asp Ala Lys Leu Thr Trp Arg Asn Asp Asn Ser His Asn Ser Gin Thr Glu Val Ala Ala Itir
TAC GCT TCC GTA GCC GTA CAG CAA CAA GAC GCG AAA TTG ACT TGG CGC AAC GAT AAT TCG CAC AAC TCT CAA ACC GAM GTET GCC CcT ACC
Ala Ala Tyr Arg Phe Gly Asn Val Thr Pro Arg Val Ser Tyr Ala His Gly Phe Lys Gly Ser Val Tyr Asp Ala Asp Asn Asp Aso i'Tr
GCG GCA TAC CGC TTC GGC AAC GTA ACG CCC CGC GTT TCT TAC GCC CAC GGC TTC AAA GGT TCG GTT TAT GAT GCA GAT AAC GAC AAT ACT
Tyr Asp Gln Val Val Val Gly Ala Glu Tyr Asp Phe Ser Lys Arg Thr Ser Ala Leu Val Ser Ala Gly Trp Leu Gln Arg Gly Lys (;ly









I ) I ,
Thr Glu Lys Phe Val Ala Thr Val Gly Gly Val Gly Leu Arg His Lys Phe
ACA GAA AAA TTC GTA GCG ACT GTC GGC GGT GTC GGT CTG CGC CAC AMA TTC TAA TCTGCAAAGATC 1076
Sau3AI
FIG. 3. DNA sequence ofthe P.I gene of FA19. The predicted amino acid sequence is shown above the DNA sequence, with the signal peptide
indicated. The putative promoter sequences (-35 and -10) and the ribosome binding site (RBS) are shown, as are the Taq I and Sau3AI sites
and the Hae III site used in the construction of pUNC7 (see Fig. 5). The last base number of each line is shown on the right.
molecular weight of the protein is 33,786, which is close to the
apparent molecular weight of 34,000 for P.J in FA19. The
signal peptide appears to have the common characteristics
associated with such sequences (28), with a stretch of
hydrophobic amino acids, an abundance of alanine residues,
and an Ala-Xaa-Ala cleavage site. There are also putative
-35 and -10 promoter sequences, which are close in
sequence and separation to the consensus for these se-
quences in E. coli (29) and a Shine-Dalgamo ribosomal
binding site (30) just upstream of the first residue of the signal
sequence. The predicted N-terminal amino acid sequence
matches that determined by amino acid sequencing of a
putative PJA protein (27) and is similiar to that of the P.IB
protein of R10 (2). The hydropathy profile of the predicted
protein is typical of that of an outer membrane porin protein
and compares favorably with the major porins of E. coli,
OmpF and OmpC (Fig. 4), characterized by long hydrophilic
regions without any substantial hydrophobic stretches. There
is little correlation with the hydropathy profiles of other
sequenced gonococcal outer membrane proteins (Fig. 4).
Construction of a P.I Gene Clone and Its Expression in E.
coli. Attempts to recover an intact P.1 gene clone by ligating
together the two portions of the gene on the Sau3AI frag-
ments of pUNC3 and pUNC15 failed repeatedly, and it was
concluded that the expression of gonococcal P.1 is lethal for
E. coli. Therefore, a recombinant plasmid, pUNC7, was
constructed such that a portion of the P.1 gene promoter was
removed and the P.I gene was positioned downstream of the
phage T7 promoter on pGEM-2 (Fig. 5). E. coli cells do not
normally contain T7 polymerase, which transcribes genes
downstream from T7 promoters, and so such a plasmid
should be stably maintained in E. coli without expression of
the P.I gene. HB101 containing pUNC7 expressed no de-
tectable P.1 in a colony radioimmunoassay. Plasmid pUNC7
was transformed into E. coli strain BL21(DE3), a lysogen in
which the phage T7 polymerase gene is present but under
control of the lacUV5 promoter (14). When grown without
iPrSGal, BL21(DE3) harboring plasmid pUNC7 produced no
detectable P.1 but, when T7 polymerase production was
induced by growth on medium containing iPrSGal, expres-
sion of P.I was detected by the P.IA monoclonal antibodies
in a colony blot radioimmunoassay (data not shown). The P.1
produced by this E. coli strain showed the same immuno-
logical reaction as that of FA19 P.1, in that it reacted with all





FIG. 4. Hydropathy patterns of the major outer membrane
proteins of N. gonorrhoeae, P.1, P.1I (J. Cannon, personal commu-
nication), and P.111 (31) and of the E. coli porins OmpF and OmpC
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FIG. 5. Scheme for construction of pUNC7. A convenient Hae III site between the -35 and -10 regions of the P.I gene promoter (see Fig.
3) allowed removal of the -35 region and the upstream sequence, followed by reconstruction of the P.1 gene under the control of the phage
T7 promoter on the vector plasmid pGEM-2. The thick line represents pGEM-2 DNA and the thin line represents FA19 DNA. P.X', portion of
the P.1 gene (the dotted line indicates the direction of the missing segment); Pan, phage 17 promoter; MCS, multiple cloning site; restriction
enzyme sites: S, Sau3AI; H, Hae III; B, BamHI; (H), Hae III/HincIl junction (no site); T, Taq I.
munoassays. The protein presumably was efficiently export-
ed through the inner membrane of the E. coli clone since it
was detectable by colony radioimmunoassay without lysis of
the cells. The protein was of equivalent apparent molecular
weight to FA19 P.A as detected by NaDodSO4/polyacryl-
A
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amide gel electrophoresis (Fig. 6A) and immunoblotting (Fig.
6B) and apparently was the most abundant protein produced
by the E. coli clone after overnight growth in the presence of
iPrSGal (Fig. 6A). However, the production of this protein
during overnight growth was lethal for this E. coli strain,
B





FIG. 6. Expression of the P.1 gene on pUNC7 in BL21(DE3). (A) NaDodSO4/polyacrylamide gel electrophoresis of whole cell lysates on
a 15% gel, stained with Coomassie blue. Sizes of marker proteins (bovine serum albumin, 69 kDa; ovalbumin, 46 kDa; carbonic anhydrase, 30
kDa; chymotrypsin, 20 kDa; lysozyme, 14 kDa) are shown to the left. P.1 is indicated, and the arrow in the center indicates a protein that is
apparently missing in lane 4. (B) Autoradiograph of an immunoblot of the gel in A probed with six PIA monoclonal antibodies. Lanes: 1, FA19;
2, BL21(DE3)pUNC7 grown 16 hr without iPrSGal; 3, BL21(DE3)pUNC7 grown 3 hr with iPrSGal; 4, BL21(DE3)pUNC7 grown 16 hr with
iPrSGal; 5, BL21(DE3)pGEM-2 grown 16 hr without iPrSGal; 6, BL21(DE3)pGEM-2 grown 16 hr with iPrSGal.
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since no viable cells were recovered from this culture,
confirming the assumption that expression of P.1 in E. coli
could not be stably maintained. The expression of one of the
major E. coli proteins apparently was greatly reduced in this
clone after overnight growth under inducing conditions (Fig.
6A). If this protein is a membrane protein, this effect may
reflect competition for sites in the membrane or a change in
the osmotic conditions for the cells that alters the membrane
protein profile.
DISCUSSION
The sequence of the gene encoding the P.1 of N. gonorrhoeae
strain FA19 predicts a protein having characteristics typical of
Gram-negative bacterial outer membrane porin proteins. Pro-
longed expression ofP.I apparently was a lethal event for the E.
coli strain used in this study, though the reason for this is
unclear. The effect may be due to osmotic destabilization ofthe
E. coli cells, either by the activity of the gonococcal porin itself
or by the displacement of the E. coli porins, or it may be due to
a change in the structural integrity of the outer membrane
complex when an abundance of the foreign protein is present.
The latter seems especially possible since E. coli is known to
regulate the total amount of its major porins, OmpF and OmpC,
in its outer membrane (33). It is possible that the expression of
P.1 would not be lethal for an E. coli strain lacking its own major
outer membrane porins, but this possibility has not been tested.
In other experiments, it was observed that subclones of the
entire P.IA insert from pUNC7 into another plasmid vector,
pHSS6 (34), resulted in mucoid "sick" colonies of HB101,
presumably because of weak expression of P.IA from a pro-
moter on this vector.
The amino acid sequences ofFA19 P.IA, deduced from the
DNA sequence here, and ofP.IB from R10 (27, 35) are similar
through the first 18 residues at the N-terminus but are
different after residue 18. This suggests a common function
for the N terminus of the protein. Using similar methods to
clone and sequence other gonococcal P.I genes, one could
compare the structure of P.IA to those of P.IB and of P.IA/
P.IB hybrids constructed by genetic transformation (19) and
thus perhaps understand more clearly the structure and function
of this protein. It is interesting to note the specificity of the
gonococcal promoter sequences recognized in E. coli. Removal
of just the -35 region of the P.1 gene promoter resulted in
complete lack ofexpression of this gene, indicating that the -35
region or other upstream sequences are necessary for efficient
transcription of the P.1 gene in E. coli.
The method of cloning the P.1 gene presented here, where
gene fragments are cloned separately and then the gene is
reconstructed with a foreign inducible promoter, may allow
cloning of other genes whose expression is deleterious to E.
coli. In addition, the use of the "chromosome walking"
method of cloning adjacent fragments should make it possible
to identify genes proximate to the cloned P.IA structural gene
on the gonococcal genome and thus establish whether the P.1
structural gene is equivalent to the nmp locus, which is
known to be closely linked to a number of loci, including one
(sac-3) that is known to affect sensitivity to serum antibody
and complement and the structure of lipopolysaccharide (W.
Shafer, personal communication). The successful cloning of
a P.1 gene will allow the construction of defined mutants of
the gene, which can then be transformed back into the
gonococcus. In addition, high-level expression of P.1 in E.
coli strains will allow purification of P.I without contamina-
tion by other gonococcal proteins, which may be important
for a variety of studies, including development of a vaccine
based on P.I.
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